EGFR and non-small cell lung carcinoma: In ClinicalTrials.gov, one registered phase III clinical study comparing osimertinib monotherapy to combination therapy with osimertinib, carboplatin, and pemetrexed for untreated patients with advanced non-squamous NSCLC with concurrent EGFR and TP53 mutations is currently undergone.